SI9420048B - Farmacevtske formulacije živčnega rastnega faktorja - Google Patents

Farmacevtske formulacije živčnega rastnega faktorja Download PDF

Info

Publication number
SI9420048B
SI9420048B SI9420048A SI9420048A SI9420048B SI 9420048 B SI9420048 B SI 9420048B SI 9420048 A SI9420048 A SI 9420048A SI 9420048 A SI9420048 A SI 9420048A SI 9420048 B SI9420048 B SI 9420048B
Authority
SI
Slovenia
Prior art keywords
formulation
water
growth factor
aqueous
nerve growth
Prior art date
Application number
SI9420048A
Other languages
English (en)
Other versions
SI9420048A (en
Inventor
M. Victoria Knepp
M. Deborah Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex (U.S.A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex (U.S.A.) Inc. filed Critical Syntex (U.S.A.) Inc.
Publication of SI9420048A publication Critical patent/SI9420048A/sl
Publication of SI9420048B publication Critical patent/SI9420048B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (13)

  1. PATENTNI ZAHTEVKI 1. Vodna farmacevtska formulacija, ki obsega: (a) živčni rastni faktor; (b) biološko sprejemljivo sol v količini, ki zadostuje za vzdrževanje izoto-ničnosti; (c) pufer v količini, ki zadostuje za vzdrževanje pH formulacije od 4,5 do 6,0; in (d) vodo in s pridržkom, da navedena formulacija ne vsebuje vodotopnega polisaharida.
  2. 2. Formulacija po zahtevku 1, označena s tem, da nadalje obsega biološko sprejemljiv vodotopen nosilec.
  3. 3. Formulacija po zahtevku 1 ali 2, označena s tem, da: (a) živčni rastni faktor obsega 0,0001 do 0,125 % glede na maso vodne formulacije; (b) nosilec obsega 0,1 do 1,25 % glede na maso vodne formulacije; (c) sol obsega 0,5 do 1,0 % glede na maso vodne formulacije; in (d) je pufer prisoten v količini, ki zadostuje za vzdrževanje pH vodne formulacije od 4,5 do 6,0.
  4. 4. Formulacija po kateremkoli od prejšnjih zahtevkov, označena s tem, da je pH od 5,0 do 5,4.
  5. 5. Vodna formulacija po kateremkoli od zahtevkov 2 do 4, označena s tem, da obsega 10 do 500 μg NGF, 5 mg/ml HSA, 8,7 mg/ml NaCl, 2,1 mg/ml citronske kisline in vodo, pri čemer je pH formulacije naravnan na 5,2.
  6. 6. Vodna farmacevtska formulacija živčnega rastnega faktorja, prikladna za liofilizacijo, označena s tem, da obsega: (a) od 1 do 1250 /ig/ml živčnega rastnega faktorja; (b) od 30 do 90 mg/ml biološko sprejemljivega pomožnega sredstva; (c) pufer v količini, ki zadostuje za vzdrževanje pH formulacije pri 5,5 do 6,5; in (d) vodo; s pridržkom, da navedena formulacija ne vsebuje vodotopnega polisaharida.
  7. 7. Formulacija po zahtevku 6, označena s tem, da je pomožno sredstvo sladkor.
  8. 8. Formulacija po kateremkoli od zahtevkov 6-7, označena s tem, da pomožno sredstvo obsega zmes saharoze in manitola, pufer je citrat, pH formulacije pa je od 5,8 do 6,2.
  9. 9. Formulacija po kateremkoli od zahtevkov 6-8, označena s tem, da je liofilizirana, da se zniža vsebnost vlage na manj kot 2 %.
  10. 10. Liofiliziran farmacevtski sestavek, označen s tem, da obsega 0,001 do 1,25 delov živčnega rastnega faktorja, 30 do 90 delov sladkorja in manj kot 1 del vode, s pridržkom, da naveden sestavek ne vsebuje vodotopnega polisaharida.
  11. 11. Formulacija ali sestavek po kateremkoli od zahtevkov 6-10, označen s tem, da nadalje obsega biološko sprejemljiv vodotopen nosilec.
  12. 12. Formulacija ali sestavek po kateremkoli od prejšnjih zahtevkov za uporabo pri zdravljenju nevronskih disfunkcij pri ljudeh.
  13. 13. Formulacija ali sestavek po zahtevku 13 v intracerebroventrikularni infuzijski obliki za uporabo pri zdravljenju Alzheimerjeve bolezni pri ljudeh.
SI9420048A 1993-08-20 1994-08-16 Farmacevtske formulacije živčnega rastnega faktorja SI9420048B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor

Publications (2)

Publication Number Publication Date
SI9420048A SI9420048A (en) 1996-10-31
SI9420048B true SI9420048B (sl) 2003-12-31

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9420048A SI9420048B (sl) 1993-08-20 1994-08-16 Farmacevtske formulacije živčnega rastnega faktorja

Country Status (32)

Country Link
US (2) US6277828B1 (sl)
EP (1) EP0721343B1 (sl)
JP (2) JP4592830B2 (sl)
KR (1) KR100341193B1 (sl)
CN (1) CN1163265C (sl)
AT (1) ATE226085T1 (sl)
AU (1) AU677699B2 (sl)
BG (1) BG62951B1 (sl)
BR (1) BR9407278A (sl)
CA (1) CA2169834C (sl)
CZ (1) CZ292422B6 (sl)
DE (1) DE69431562T2 (sl)
DK (1) DK0721343T3 (sl)
ES (1) ES2181723T3 (sl)
FI (1) FI113241B (sl)
HK (1) HK1012990A1 (sl)
HU (1) HU228152B1 (sl)
IL (3) IL110725A (sl)
LT (1) LT4051B (sl)
LV (1) LV11279B (sl)
NO (1) NO317627B1 (sl)
NZ (1) NZ271873A (sl)
PL (1) PL176387B1 (sl)
PT (1) PT721343E (sl)
RO (1) RO114742B1 (sl)
RU (1) RU2126265C1 (sl)
SI (1) SI9420048B (sl)
SK (1) SK284064B6 (sl)
TW (1) TW427905B (sl)
UA (1) UA43348C2 (sl)
WO (1) WO1995005845A1 (sl)
ZA (1) ZA946333B (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
CA2220897A1 (en) * 1995-05-12 1996-11-14 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
IL124004A (en) * 1995-11-07 2003-10-31 Genentech Inc Stable pharmaceutical composition comprising ngf
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
WO1997045009A2 (en) * 1996-05-29 1997-12-04 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
WO1998048832A1 (en) * 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
EP1605968A2 (en) * 2003-03-18 2005-12-21 Novo Nordisk Health Care AG Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE454900T1 (de) * 2003-05-23 2010-01-15 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
PL2298287T3 (pl) * 2003-12-19 2019-02-28 Novo Nordisk Health Care Ag Stabilizowane kompozycje polipeptydów czynnika VII
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
JPWO2008020584A1 (ja) * 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
ES2407413T3 (es) * 2006-11-08 2013-06-12 P Mind Co., Ltd Aparato para acelerar la producción de factor neurotrófico
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
KR20110061639A (ko) * 2008-09-26 2011-06-09 아도시아 폴리사카라이드 및 ｈｐｂ로 구성된 복합체
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
KR102017905B1 (ko) 2011-04-07 2019-09-03 니오베크스 Ifn 알파 관련 질환을 치료하는 방법
BR112014019576A8 (pt) * 2012-02-08 2017-07-11 Agronomique Inst Nat Rech Fator de crescimento de nervos beta, composição farmacêutica e método para induzir a ovulação
ES2893239T3 (es) * 2015-04-21 2022-02-08 Staidson Beijing Biopharmaceuticals Co Ltd Composición de factor de crecimiento nervioso y polvo de inyección
DK3287140T3 (da) * 2015-04-21 2021-07-19 Beijing Staidson Medical Tech Co Ltd Nervevækstfaktorsammensætning og pulverinjektion
WO2016169455A1 (zh) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物和注射粉剂
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
US20200299371A1 (en) 2016-03-25 2020-09-24 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
LT3463308T (lt) * 2016-06-01 2022-02-10 Servier IP UK Limited Polialkilenoksido-asparaginazės vaisto formos ir jų gamybos būdai bei panaudojimas
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
JP2007314572A (ja) 2007-12-06
LT4051B (en) 1996-10-25
DE69431562T2 (de) 2003-06-18
KR100341193B1 (ko) 2002-06-21
CA2169834C (en) 2008-11-04
NO960651D0 (no) 1996-02-19
FI960750A0 (fi) 1996-02-19
US7074763B2 (en) 2006-07-11
CZ292422B6 (cs) 2003-09-17
BG62951B1 (bg) 2000-12-29
DE69431562D1 (de) 2002-11-21
SI9420048A (en) 1996-10-31
IL124941A0 (en) 1999-01-26
HUT74728A (en) 1997-02-28
ZA946333B (en) 1996-02-19
NZ271873A (en) 1996-10-28
FI960750A (fi) 1996-02-20
UA43348C2 (uk) 2001-12-17
HU228152B1 (en) 2012-12-28
AU7566894A (en) 1995-03-21
DK0721343T3 (da) 2003-02-17
FI113241B (fi) 2004-03-31
PL176387B1 (pl) 1999-05-31
HK1012990A1 (en) 1999-08-13
EP0721343A1 (en) 1996-07-17
WO1995005845A1 (en) 1995-03-02
IL124941A (en) 2006-12-10
LT96011A (en) 1996-07-25
US20010007662A1 (en) 2001-07-12
US6277828B1 (en) 2001-08-21
AU677699B2 (en) 1997-05-01
JPH10508000A (ja) 1998-08-04
HU9600371D0 (en) 1996-04-29
BG100371A (bg) 1996-12-31
EP0721343B1 (en) 2002-10-16
CN1133012A (zh) 1996-10-09
SK284064B6 (sk) 2004-09-08
SK18396A3 (en) 1996-10-02
CN1163265C (zh) 2004-08-25
CZ42496A3 (en) 1996-05-15
NO317627B1 (no) 2004-11-29
LV11279A (lv) 1996-06-20
LV11279B (en) 1996-10-20
JP4592830B2 (ja) 2010-12-08
NO960651L (no) 1996-02-19
PT721343E (pt) 2003-01-31
BR9407278A (pt) 1996-10-01
ATE226085T1 (de) 2002-11-15
RO114742B1 (ro) 1999-07-30
TW427905B (en) 2001-04-01
PL313084A1 (en) 1996-05-27
IL110725A (en) 2004-09-27
RU2126265C1 (ru) 1999-02-20
CA2169834A1 (en) 1995-03-02
ES2181723T3 (es) 2003-03-01
IL110725A0 (en) 1994-11-11

Similar Documents

Publication Publication Date Title
SI9420048B (sl) Farmacevtske formulacije živčnega rastnega faktorja
RU96105951A (ru) Фармацевтические композиции с фактором роста нерва
DE69532970T3 (de) Sprühgetrocknetes erythropoietin
US5456922A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4824938A (en) Water-soluble dry solid containing proteinaceous bioactive substance
RU99118890A (ru) Водорастворимая фармацевтическая композиция в виде ионного комплекса и ее применение
CA2019466C (en) Minerals in bioavailable form
KR890003400A (ko) 경비(經鼻)투여용 생리 활성 펩티드 분말 조성물(제제)
KR950702834A (ko) 글루칸 제제(novel glucan preparation)
JP2001010960A (ja) 局所用亜鉛組成物および使用方法
PT86075B (pt) Proceso para a estabilizacao de composicoes que contem um factor de crescimento de polipeptideo
CA2329000A1 (en) Stabilised virus preparation
KR960700062A (ko) 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH)
DE60028152T2 (de) Fester, stabiler und konzentrierter biologisch verdaulicher Komplex von Orthokieselsäure und Prozess zur dessen Herstellung
CA1115206A (en) Method for preparing urokinase injection
DE04007657T1 (de) Pharmazeutische Zusammensetzung aus fibrinolytischem Mittel
JPS6326120B2 (sl)
DE3782828T2 (de) Interleukin-2-zusammensetzungen.
CA2121345A1 (en) Lipophilic Oligosaccharide Antibiotic Salt Compositions
DE69925820T2 (de) Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
US3940480A (en) Process for production of stabilized powdery secretin preparation by lyophilization
EP1450825B1 (de) Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung
NZ516507A (en) Growth hormone formulations that are resistant to crystallisation
EP0458930B1 (de) STABILISIERUNG VON GLYKOSYLIERTEM t-PA
DE3942141A1 (de) K2p pro-stabilisierung

Legal Events

Date Code Title Description
IF Valid on the event date